[go: up one dir, main page]

RU2003122061A - ANTIATEROSCLEROTIC COMPOSITION CONTAINING CAROTINOIDS AND METHOD FOR INHIBITING OXIDATION OF LOW DENSITY Lipoprotein (LDL) - Google Patents

ANTIATEROSCLEROTIC COMPOSITION CONTAINING CAROTINOIDS AND METHOD FOR INHIBITING OXIDATION OF LOW DENSITY Lipoprotein (LDL)

Info

Publication number
RU2003122061A
RU2003122061A RU2003122061/14A RU2003122061A RU2003122061A RU 2003122061 A RU2003122061 A RU 2003122061A RU 2003122061/14 A RU2003122061/14 A RU 2003122061/14A RU 2003122061 A RU2003122061 A RU 2003122061A RU 2003122061 A RU2003122061 A RU 2003122061A
Authority
RU
Russia
Prior art keywords
phytofluene
phytoene
composition
mixture
ldl
Prior art date
Application number
RU2003122061/14A
Other languages
Russian (ru)
Other versions
RU2288707C2 (en
Inventor
Моррис ЗЕЛХА
Таня СЕДЛОВ
Зохар НИР
Original Assignee
Лайкорид Нэчрэл Продактс Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL141039A external-priority patent/IL141039A/en
Application filed by Лайкорид Нэчрэл Продактс Индастриз Лтд. filed Critical Лайкорид Нэчрэл Продактс Индастриз Лтд.
Publication of RU2003122061A publication Critical patent/RU2003122061A/en
Application granted granted Critical
Publication of RU2288707C2 publication Critical patent/RU2288707C2/en

Links

Claims (28)

1. Способ ингибирования развития атеросклероза, включающий введение пациенту, нуждающемуся в лечении, эффективного для антиокисления LDL количества фитоена, фитофлуена или их смесей.1. A method of inhibiting the development of atherosclerosis, comprising administering to a patient in need of treatment an effective amount of phytoene, phytofluene, or mixtures thereof, for antioxidation of LDL. 2. Способ по п.1, в котором пациенту, нуждающемуся в лечении, вводят по меньшей мере 0,2 мг/сутки препарата.2. The method according to claim 1, in which at least 0.2 mg / day of the drug is administered to a patient in need of treatment. 3. Способ по п.1, в котором вводят смесь фитоена и фитофлуена.3. The method according to claim 1, wherein a mixture of phytoene and phytofluene is administered. 4. Способ по п.3, в котором отношение фитоена и фитофлуена в смеси находится в диапазоне от около 1:20 до около 20:1.4. The method according to claim 3, in which the ratio of phytoene and phytofluene in the mixture is in the range from about 1:20 to about 20: 1. 5. Способ по п.1, в котором введение осуществляют в виде суточной дозы.5. The method according to claim 1, in which the introduction is carried out in the form of a daily dose. 6. Способ по п.1, в котором фитоен, фитофлуен или их смеси вводят вместе с обычными антиатеросклеротическими агентами.6. The method according to claim 1, in which the phytoene, phytofluene or mixtures thereof are administered together with conventional antiatherosclerotic agents. 7. Способ по п.1, в котором введение проводят таким образом, чтобы достигнуть эффективной для анти-LDL-окисления концентрации фитоена, фитофлуена или их смесей в крови, причем указанная концентрация составляет по меньшей мере 0,01 мкМ.7. The method according to claim 1, in which the introduction is carried out in such a way as to achieve an effective anti-LDL oxidation concentration of phytoen, phytofluene or mixtures thereof in the blood, and the specified concentration is at least 0.01 μm. 8. Антиатеросклеротическая композиция, включающая эффективное для ингибирования окисления LDL количество фитоена, фитофлуена или их смесей.8. Anti-atherosclerotic composition comprising an effective amount of phytoene, phytofluene, or mixtures thereof, to inhibit LDL oxidation. 9. Композиция по п.8, включающая по меньшей мере 0,1 мг фитоена.9. The composition of claim 8, comprising at least 0.1 mg of phytoene. 10. Композиция по п.8, включающая по меньшей мере 0,1 мг фитофлуена.10. The composition of claim 8, comprising at least 0.1 mg of phytofluene. 11. Композиция по п.8, включающая по меньшей мере 0,1 мг смеси фитоена и фитофлуена.11. The composition of claim 8, comprising at least 0.1 mg of a mixture of phytoene and phytofluene. 12. Композиция по п.11, в которой отношение фитоена и фитофлуена в смеси находится в диапазоне от около 1:20 до около 20:1.12. The composition according to claim 11, in which the ratio of phytoene and phytofluene in the mixture is in the range from about 1:20 to about 20: 1. 13. Композиция по п.8 в форме твердых дозированных таблеток, капсул, капсул с твердой оболочкой, гелевых капсул или мягких гелей.13. The composition of claim 8 in the form of solid dosage tablets, capsules, hard-shell capsules, gel capsules or soft gels. 14. Композиция по п.8, включающая фармацевтически приемлемый адъювант, наполнитель или добавку.14. The composition of claim 8, comprising a pharmaceutically acceptable adjuvant, excipient or additive. 15. Применение композиции, включающей фитоен, фитофлуен или их смеси, для ингибирования окисления LDL.15. The use of a composition comprising phytoen, phytofluene, or mixtures thereof, for inhibiting the oxidation of LDL. 16. Применение композиции по п.15 вместе с обычным антиатеросклеротическим агентом.16. The use of a composition according to claim 15 together with a conventional anti-atherosclerotic agent. 17. Применение фитоена, фитофлуена или их смеси для приготовления медицинского препарата для ингибирования окисления LDL и развития атеросклероза.17. The use of phytoene, phytofluene or a mixture thereof for the preparation of a medicament for inhibiting the oxidation of LDL and the development of atherosclerosis. 18. Применение по п.17, в котором медицинский препарат включает эффективное для ингибирования окисления LDL количество фитоена, фитофлуена или их смеси.18. The use of claim 17, wherein the medicament comprises an effective amount of phytoene, phytofluene, or a mixture thereof, to inhibit LDL oxidation. 19. Применение по п.18, в котором медицинский препарат включает по меньшей мере 0,1 мг фитоена.19. The use of claim 18, wherein the medicament comprises at least 0.1 mg of phytoene. 20. Применение по п.18, в котором медицинский препарат включает по меньшей мере 0,1 мг фитофлуена.20. The use of claim 18, wherein the medicament comprises at least 0.1 mg of phytofluene. 21. Применение по п.18, в котором медицинский препарат включает по меньшей мере 0,1 мг смеси фитоена и фитофлуена.21. The use of claim 18, wherein the medicament comprises at least 0.1 mg of a mixture of phytoene and phytofluene. 22. Применение по п.21, в котором отношение фитоена и фитофлуена в смеси находится в диапазоне от около 1:20 до около 20:1.22. The use according to item 21, in which the ratio of phytoene and phytofluene in the mixture is in the range from about 1:20 to about 20: 1. 23. Применение эффективного для анти-LDL-окисления количества фитоена, фитофлуена или их смесей для приготовления функциональных пищевых продуктов, диетических добавок, пищевых продуктов и напитков.23. The use of an effective anti-LDL oxidation amount of phytoene, phytofluene or mixtures thereof for the preparation of functional foods, dietary supplements, foods and drinks. 24. Применение по п.23, в котором по меньшей мере 0,1 мг фитоена и фитофлуена или их смеси добавляют к функциональным пищевым продуктам, диетическим добавкам, пищевым продуктам и напиткам.24. The use according to claim 23, in which at least 0.1 mg of phytoene and phytofluene or mixtures thereof are added to functional foods, dietary supplements, foods and drinks. 25. Способ, по существу, как он описан и проиллюстрирован примерами.25. The method, essentially as it is described and illustrated by examples. 26. Применение композиции, по существу, как она описана и проиллюстрирована примерами.26. The use of the composition, essentially as it is described and illustrated by examples. 27. Композиция по существу как она описана и проиллюстрирована примерами.27. The composition is essentially as described and illustrated by examples. 28. Фармацевтическая композиция, по существу, как она описана и проиллюстрирована примерами.28. A pharmaceutical composition, essentially as described and illustrated by examples.
RU2003122061/14A 2001-01-23 2002-01-21 Carotinoid-containing anti-atherosclerotic composition and method for inhibition of oxidation of low density lipoprotein (ldl) RU2288707C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL141039A IL141039A (en) 2001-01-23 2001-01-23 Anti-atherosclerosis composition containing carotenoids and use in the preparation of medicaments for inhibiting ldl oxidation
IL141039 2001-01-23

Publications (2)

Publication Number Publication Date
RU2003122061A true RU2003122061A (en) 2004-10-27
RU2288707C2 RU2288707C2 (en) 2006-12-10

Family

ID=11075060

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003122061/14A RU2288707C2 (en) 2001-01-23 2002-01-21 Carotinoid-containing anti-atherosclerotic composition and method for inhibition of oxidation of low density lipoprotein (ldl)

Country Status (16)

Country Link
US (2) US7351746B2 (en)
EP (1) EP1363609B1 (en)
JP (2) JP4405151B2 (en)
KR (1) KR100841238B1 (en)
CN (1) CN1273119C (en)
AT (1) ATE471716T1 (en)
AU (1) AU2002226652B2 (en)
BR (1) BR0206942A (en)
CA (1) CA2435613C (en)
DE (1) DE60236787D1 (en)
ES (1) ES2346047T3 (en)
IL (1) IL141039A (en)
NO (1) NO20033232L (en)
PL (1) PL208263B1 (en)
RU (1) RU2288707C2 (en)
WO (1) WO2002058682A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141038A (en) * 2001-01-23 2006-10-05 Lycored Natural Prod Ind Ltd Use of carotenoids in the preparation of anti-hypertension agents
IL141039A (en) * 2001-01-23 2006-10-31 Lycored Natural Prod Ind Ltd Anti-atherosclerosis composition containing carotenoids and use in the preparation of medicaments for inhibiting ldl oxidation
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
BRPI0313155B8 (en) 2002-07-29 2021-05-25 Cardax Pharmaceuticals Inc chemical compound derived or carotenoid analogue, pharmaceutical composition, and use of the compound
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US7521584B2 (en) 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
EP1750723A1 (en) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20090099061A1 (en) * 2006-01-27 2009-04-16 Foss Bente J Synthesis of carotenoid analogs or derivatives with improved antioxidant characteristics
IL176668A0 (en) * 2006-07-02 2006-10-31 Ibr Ltd Colorless carotenoids for skin whitening
US8063101B2 (en) * 2007-03-23 2011-11-22 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives for the prevention of platelet aggregation
BRPI1005154A2 (en) * 2009-01-19 2018-02-06 Lycored Ltd "therapeutic composition, method for inhibiting or reducing the production of superoxide ions, nitric oxide (n), tumor necrosis factor alpha (tnf-alpha) and / or prostaglandin e2 (pge2) in a mammalian subject, methods of treatment and use of a combination"
WO2017029674A1 (en) * 2015-08-20 2017-02-23 I.B.R. Israeli Biotechnology Research Ltd. Carotenoid compositions having antiviral activities and uses thereof
JP7492222B2 (en) * 2018-04-18 2024-05-29 国立大学法人京都大学 Adiponectin receptor agonist and use thereof, and food composition for activating adiponectin receptor and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4A (en) * 1836-08-10 Thomas Blanchard Stock shaving or rounding machine for edges ends etc of ships' tackle-blocks
US4046880A (en) 1976-04-20 1977-09-06 The University Of Virginia Method of treating hypertension
US6132790A (en) * 1991-09-06 2000-10-17 Betatene Limited Carotenoid composition
RU2095059C1 (en) * 1993-07-27 1997-11-10 Товарищество с ограниченной ответственностью "Инвест" Method of prophylaxis and treatment of atherosclerosis
US5643623A (en) 1995-06-07 1997-07-01 Mars Incorporated Health food product and its uses
US5854015A (en) 1995-10-31 1998-12-29 Applied Food Biotechnology, Inc. Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion
US5705624A (en) 1995-12-27 1998-01-06 Fitzmaurice; Wayne Paul DNA sequences encoding enzymes useful in phytoene biosynthesis
RU2118528C1 (en) * 1996-01-16 1998-09-10 Казарян Роберт Врамович Composition for preparing medicinal forms and foodstuffs enriching
US20040191297A1 (en) * 1997-05-22 2004-09-30 Lance Schlipalius Carotenoid formulation
AUPO693397A0 (en) * 1997-05-22 1997-06-12 Betatene Limited Carotenoid formulation
DK0996431T3 (en) * 1997-06-19 2004-04-26 Lycored Natural Prod Ind Ltd Synergistic preparations of lycopene and vitamin E to prevent LDL oxidation
IL123132A (en) * 1998-02-01 2003-10-31 Lycored Natural Prod Ind Ltd Synergistic composition for preventing ldl oxidation and arresting the progression of atherosclerosis, comprising lycopene and garlic
IL126076A (en) * 1998-09-04 2005-05-17 Ibr Ltd Transparent composition comprising phytoene and phytofluene
GB9922751D0 (en) * 1999-09-27 1999-11-24 Kenton Corp Limited A pharmaceutical composition for stabilising atherosclerotic plaques
DE10036797A1 (en) 2000-07-28 2002-02-07 Beiersdorf Ag Use of combinations containing carnitines
IL141038A (en) 2001-01-23 2006-10-05 Lycored Natural Prod Ind Ltd Use of carotenoids in the preparation of anti-hypertension agents
IL141039A (en) * 2001-01-23 2006-10-31 Lycored Natural Prod Ind Ltd Anti-atherosclerosis composition containing carotenoids and use in the preparation of medicaments for inhibiting ldl oxidation
IL146496A0 (en) 2001-11-14 2002-07-25 Lycored Natural Prod Ind Ltd Carotenoid composition and method for protecting skin

Similar Documents

Publication Publication Date Title
RU2003122061A (en) ANTIATEROSCLEROTIC COMPOSITION CONTAINING CAROTINOIDS AND METHOD FOR INHIBITING OXIDATION OF LOW DENSITY Lipoprotein (LDL)
JP5947721B2 (en) Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations for treating osteoarthritis
US20060003947A1 (en) Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US10617660B2 (en) Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
CN1507350A (en) N-acetylcysteine compositions and methods for treatment and prevention of drug intoxication
CA2767833A1 (en) N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
JP2004516257A (en) Compositions and methods for treating diabetic neuropathy
WO2008044691A1 (en) Antidepressant agent
RU2290174C2 (en) Carotinoids as anti-hypertensive agents
RU2528897C2 (en) Formulation for oral transmucosal use of lipid-lowering agents
US6017946A (en) Serotonin containing formulation for oral administration and method of use
RU2003122060A (en) CAROTINOIDS AS ANTIHYPERTENSIVE AGENTS
JP2011088939A (en) Internal pharmaceutical preparation
JP2005524629A (en) Jojoba products for reducing body weight, blood lipid levels and for cancer prevention and treatment
KR20070003995A (en) Compositions with Reduced Hepatotoxicity
JP4850402B2 (en) Oral preparation
JP6771274B2 (en) Oral composition
RU2152221C1 (en) Agent with hepatoprotective, cholesterol and glucose content regulating effect
US5670549A (en) Prevention and amelioration of liver toxicity with beta-carotene
JP3253878B2 (en) Formulations for iron chelation, methods of preparing the same and methods of treating Mediterranean anemia
KR20150143504A (en) Method and products for enhancing drug and dietary supplement bioavailability
JP5241127B2 (en) Analgesic composition
KR100379155B1 (en) New analgesic composition
RU2174836C1 (en) Pharmaceutical composition eliciting analgesic effect
Tulp et al. Can trans-3’5’4-trihydroxystilbene (resveratrol) become an effective adjunct in the treatment of sickle cell disease